Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05293756 · ClinicalTrials.gov registry record · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
A NA study of Hypertension and Quality of Life, sponsored by Case Western Reserve University.
- Recruiting
- Registry status
- NA
- Development phase
- 208
- Enrollment target
- 1
- Study location
NCT05293756: Recruiting NA study of Hypertension and Quality of Life, sponsored by Case Western Reserve University.
NCT05293756 is a NA study of Hypertension and Quality of Life that is actively recruiting participants, run by Case Western Reserve University. The registered enrollment target is 208 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05293756, a NA study of Hypertension and Quality of Life, is actively recruiting participants, sponsored by Case Western Reserve University.
- RECRUITING
- Registry status
- NA
- Development phase
- 208 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypertension (HTN) has a greater impact on African Americans (AA) than any other U.S. racial group. Uncontrolled blood pressure (BP) contributes to higher rates of disability, death, and health resource use among AA. HTN is the single most influential risk factor for cardiovascular disease (CVD), as well as a risk factor for the incidence of stroke, diabetes, chronic kidney disease, and dementia. Importantly, older adults account for 15% of the U.S. population, and two-thirds of older adults over age 60 have HTN, with higher rates observed in AA older adults. Strategies to support self-managing HTN and BP control are crucial as the older population is projected to age considerably and become more racially and ethnically diverse. Research has documented the negative effects on health and health outcomes of poorly controlled BP and is one of the most important modifiable CVD risk factors. Lower BP targets will require aggressive management and an increase in antihypertensive medications. Therefore, to achieve lower targets in this population, greater efforts, including patient-centered methods will be needed to support self-managing HTN, especially in terms of medication adherence. As we shifted into the digital age, the use of mHealth technologies (smart phones, applications, SMS or text messaging) has been a powerful approach and mechanism for the treatment and management of chronic diseases. However, behavioral interventions that incorporate technology do not reach minorities or disadvantaged AA older adults with HTN. OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP) will leverage existing knowledge of effective technology-based components for HTN self-management to support and improve BP control using unique aspects of mHealth platforms in AA older adults. Findings from this study, if confirmed, will improve BP control and support self-managing HTN, as well as has the potential to close the health disparity gap between AA and non-AA
Primary Outcome
Systolic BP \< 130 mmHg or Diastolic BP \< 80 mmHg, represents improved blood pressure control, measured digitally using a standard automatic BP device (Omron HEM-907 XL).
Conditions Studied
Interventions
- BEHAVIORAL OPTIMA-BP Intervention
Study Locations (1)
Ohio
- Case Western Reserve University - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2021-02-14 |
| Est. Completion | 2027-05-31 |
| Phase | NA |
What NCT05293756 shows while recruiting
NCT05293756 is an interventional study that assigns participants to a tested intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (94% lower).
The record links to 4 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which OPTIMA-BP Intervention is the first listed.
NCT05293756 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05293756 about?
NCT05293756 is a clinical study titled "OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)". Hypertension (HTN) has a greater impact on African Americans (AA) than any other U.S. racial group. Uncontrolled blood pressure (BP) contributes to higher rates of disability, death, and health resource use among AA. HTN is the single most influential risk factor for cardiovascular disease (CVD), as...
What is the current status of trial NCT05293756?
This trial is currently recruiting. It is a NA study. The enrollment target is 208 participants. The study started on 2021-02-14. Estimated completion is 2027-05-31.
What conditions does trial NCT05293756 study?
This clinical trial studies the following conditions: Hypertension, Quality of Life, Self-management, Technology.
What interventions are being tested in trial NCT05293756?
The interventions under investigation include: OPTIMA-BP Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05293756?
This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05293756 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05293756's enrollment target sits among peer trials
208 214th of 470 higher than 256 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes
RECRUITING · NA
-
Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients
RECRUITING · NA
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Early Time-Restricted Eating in Older Adults With Hypertension
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05713695 · 208 participants · NA
Supporting Treatment Access and Recovery Through Linkage and Support
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI